Integrated genomic and epigenomic analysis of circulating tumor DNA from patients with BRAF V600-mutant melanoma
- Conditions
- malignant melanoma
- Registration Number
- JPRN-UMIN000051210
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Not provided
1. A history of active malignancy within 5 years of disease-free status. However, patients with basal cell carcinoma or squamous cell carcinoma of the skin, superficial bladder cancer, cervical cancer, endoscopically curable carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma equivalent lesions, or non-metastatic prostate cancer that does not require systemic treatment, who are judged to be cured by local treatment, will be enrolled in the registry if they are disease-free for 5 years or less It shall be possible. 2. Duplicate cancers are suspected on the head, neck, thorax, abdomen, and pelvic contrast CT scan within 84 days before enrollment *1*2. 3. Women who are pregnant or breastfeeding 4. Attending physician determines that the subject is unsuitable for enrollment in this study. *1 Subjects with allergies/sensitivities to contrast media, etc. may be performed without contrast media. *2 Contrast brain CT can be replaced with brain MRI.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive rate of Guardant Reveal assay before/during/after adjuvant therapy and its correlation with prognosis
- Secondary Outcome Measures
Name Time Method